Minerva Neurosciences Announces the NDA Filing for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
01. Mai 2023 07:00 ET
|
Minerva Neurosciences, Inc
BURLINGTON, Mass., May 01, 2023 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
Minerva Neurosciences Submits New Drug Application to FDA for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia
22. August 2022 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...
IntelGenx Facility Undergoes U.S. FDA Pre-Approval Inspection Related to RIZAPORT® NDA
30. Januar 2019 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Jan. 30, 2019 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) (“IntelGenx”), a leading oral drug delivery company, today announced that the U.S. Food and Drug...
IntelGenx Announces Successful Results from RIZAPORT® Bioequivalence Study
24. September 2018 08:00 ET
|
IntelGenx Technologies Corp.
SAINT LAURENT, Quebec, Sept. 24, 2018 (GLOBE NEWSWIRE) -- IntelGenx Corp. (TSX-V: IGX) (OTCQX: IGXT) (the “Company” or “IntelGenx”) today announced successful results from a bioequivalence study for...